Intent To Grant an Exclusive License of a U.S. Government-Owned Invention, 1848 [2013-00226]
Download as PDF
<![CDATA[
1848
Federal Register / Vol. 78, No. 6 / Wednesday, January 9, 2013 / Notices
Del Norte County, California,’’ evaluated
the impacts on the human environment
of our authorization of incidental Level
B harassment resulting from the
specified activity in the specified
geographic region. At that time, we
concluded that issuance of an IHA
November 1 through April 30, annually
would not significantly affect the
quality of the human environment and
issued a Finding of No Significant
Impact (FONSI) for the 2010 EA
regarding the Society’s activities. In
conjunction with the Society’s 2012
application, we have again reviewed the
2010 EA and determined that there are
no new direct, indirect or cumulative
impacts to the human and natural
environment associated with the IHA
requiring evaluation in a supplemental
EA and we, therefore, intend to
preliminarily reaffirm the 2010 FONSI.
An electronic copy of the EA and the
FONSI for this activity is available upon
request (see ADDRESSES).
619–7808; both at telefax (301) 619–
5034.
SUPPLEMENTARY INFORMATION: Anyone
wishing to object to grant of this license
can file written objections along with
supporting evidence, if any, within 15
days from the date of this publication.
Written objections are to be filed with
the Command Judge Advocate (see
ADDRESSES).
Helen M. Golde,
Acting Office Director, Office of Protected
Resources, National Marine Fisheries Service.
ACTION:
[FR Doc. 2013–00202 Filed 1–8–13; 8:45 am]
BILLING CODE 3510–22–P
Department of the Army
Intent To Grant an Exclusive License
of a U.S. Government-Owned Invention
Department of the Army, DoD.
Notice.
AGENCY:
In accordance with 35 U.S.C.
209(e), and 37 CFR 404.7(a)(1)(i) and 37
CFR 404.7(b)(1)(i), announcement is
made of the intent to grant an exclusive,
revocable license to the invention
claimed in U.S. Patent No. 6,316,197,
entitled ‘‘Method of Diagnosing of
Exposure to Toxic Agents by Measuring
Distinct Pattern in the Levels of
Expression of Specific Genes,’’ issued
on November 13, 2001, and foreign
rights to Cascade Biotherapeutics, Inc.,
with its principal place of business at
4938 Hampden Lane #319, Bethesda,
Maryland 20814–2914.
ADDRESSES: Commander, U.S. Army
Medical Research and Materiel
Command, ATTN: Command Judge
Advocate, MCMR–JA, 504 Scott Street,
Fort Detrick, MD 21702–5012.
FOR FURTHER INFORMATION CONTACT: For
licensing issues, Dr. Paul Mele, Office of
Research & Technology Applications,
(301) 619–6664. For patent issues, Ms.
Elizabeth Arwine, Patent Attorney, (301)
srobinson on DSK4SPTVN1PROD with
SUMMARY:
VerDate Mar<15>2010
18:09 Jan 08, 2013
[FR Doc. 2013–00226 Filed 1–8–13; 8:45 am]
BILLING CODE 3710–08–P
DEPARTMENT OF ENERGY
Plutonium-238 Production for
Radioisotope Power Systems for
National Aeronautics and Space
Administration and National Security
Missions
Department of Energy.
Notice of Intent to Prepare a
Supplement Analysis; Notice of
Cancellation of an Environmental
Impact Statement.
AGENCY:
The Department of Energy
(DOE) issued the Programmatic
Environmental Impact Statement for
Accomplishing Expanded Civilian
Nuclear Energy Research and
Development and Isotope Production
Missions in the United States, Including
the Role of the Fast Flux Test Facility
(Nuclear Infrastructure or NI PEIS) in
December 2000 to evaluate alternatives
for enhancement of DOE’s nuclear
infrastructure. After considering the
analysis in the NI PEIS and other
relevant factors, DOE decided to
reestablish domestic production of
plutonium-238 (Pu-238) for radioisotope
power systems (RPSs) to support the
National Aeronautics and Space
Administration (NASA) and national
security missions. Although a Record of
Decision (ROD) for the NI PEIS was
published in January 2001, DOE has not
implemented the decision to date. That
decision included using the Advanced
Test Reactor at the Idaho National
Laboratory (INL) and the High Flux
Isotope Reactor at the Oak Ridge
National Laboratory (ORNL) in
Tennessee to irradiate neptunium-237
(Np-237) targets; using the
Radiochemical Engineering
Development Center at ORNL to
fabricate Np-237 targets and isolate Pu238; utilizing TA-55 at Los Alamos
National Laboratory in New Mexico to
purify and encapsulate Pu-238; and,
using existing facilities at INL to
assemble and test the RPSs. Subsequent
SUMMARY:
DEPARTMENT OF DEFENSE
ACTION:
Brenda S. Bowen,
Army Federal Register Liaison Officer.
Jkt 229001
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
to the decision, DOE issued the draft
Environmental Impact Statement for the
Proposed Consolidation of Nuclear
Operations Related to Production of
Radioisotope Power Systems (Draft
Consolidation EIS) in 2005 to
consolidate the nuclear operations
related to RPSs at a single site. DOE is
now proposing to implement that earlier
decision based on the NI PEIS and
cancel the Consolidation EIS. Prior to
proceeding with implementation of that
earlier decision, DOE will prepare a
Supplement Analysis (SA) in
accordance with DOE’s National
Environmental Policy Act (NEPA)
Implementing Procedures to determine
whether a supplement to the NI PEIS or
a new EIS should be prepared, or that
no additional NEPA review is
warranted.
FOR FURTHER INFORMATION CONTACT: For
further information on the Pu–238
Production Program, please contact: Ms.
Alice Caponiti, Program Director for
Infrastructure Capabilities, Office of
Space and Defense Power Systems (NE–
75), Office of Nuclear Energy, U.S.
Department of Energy, 1000
Independence Ave. SW., Washington,
DC 20585, Phone 301–903–6062,
alice.caponiti@nuclear.energy.gov.
For information on NEPA analysis for
Pu-238 production, please contact: Dr.
Rajendra Sharma, NEPA Compliance
Officer, Office of Nuclear Energy (NE–
31), U.S. Department of Energy, 1000
Independence Ave. SW., Washington,
DC 20585, Phone 301–903–2899,
rajendra.sharma@nuclear.energy.gov.
For general information on the DOE
NEPA process, please contact: Ms. Carol
Borgstrom, Director, Office of NEPA
Policy and Compliance (GC–54), U.S.
Department of Energy, 1000
Independence Ave. SW., Washington,
DC 20585, Phone 202–586–4600; leave a
message at 1–800–472–2756; facsimile
202–586–7031; or send email to:
asknepa@hq.doe.gov.
SUPPLEMENTARY INFORMATION:
Background
Under the authority of the Atomic
Energy Act of 1954, DOE’s missions
include: (1) Producing isotopes for
research and applications in medicine
and industry; (2) meeting nuclear
material needs of other Federal
agencies; and (3) conducting research
and development activities for civilian
use of nuclear power. As part of these
responsibilities, DOE and its
predecessor agencies have supplied Pu238 for U.S. space programs and
national security missions for more than
five decades. NASA uses RPSs, which
are fueled by Pu-238, as the source of
E:\FR\FM\09JAN1.SGM
09JAN1
]]>Agencies
[Federal Register Volume 78, Number 6 (Wednesday, January 9, 2013)]
[Notices]
[Page 1848]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-00226]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Department of the Army
Intent To Grant an Exclusive License of a U.S. Government-Owned
Invention
AGENCY: Department of the Army, DoD.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In accordance with 35 U.S.C. 209(e), and 37 CFR 404.7(a)(1)(i)
and 37 CFR 404.7(b)(1)(i), announcement is made of the intent to grant
an exclusive, revocable license to the invention claimed in U.S. Patent
No. 6,316,197, entitled ``Method of Diagnosing of Exposure to Toxic
Agents by Measuring Distinct Pattern in the Levels of Expression of
Specific Genes,'' issued on November 13, 2001, and foreign rights to
Cascade Biotherapeutics, Inc., with its principal place of business at
4938 Hampden Lane 319, Bethesda, Maryland 20814-2914.
ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command,
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick,
MD 21702-5012.
FOR FURTHER INFORMATION CONTACT: For licensing issues, Dr. Paul Mele,
Office of Research & Technology Applications, (301) 619-6664. For
patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808;
both at telefax (301) 619-5034.
SUPPLEMENTARY INFORMATION: Anyone wishing to object to grant of this
license can file written objections along with supporting evidence, if
any, within 15 days from the date of this publication. Written
objections are to be filed with the Command Judge Advocate (see
ADDRESSES).
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2013-00226 Filed 1-8-13; 8:45 am]
BILLING CODE 3710-08-P
